Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 3/20 | 0.45 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.45 |
| ▸ | HCRTR2 | O43614 | 6/20 | 0.44 |
| ▸ | OXTR | P30559 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6573645 | 0.87 | KEAP1 (0.48) | KEAP1NFE2L2HCRTR2OXTRGAA | |
| SCHEMBL6571973 | 0.84 | MAPT (0.44) | KEAP1NFE2L2HCRTR2OXTRMAPT | |
| SCHEMBL6767214 | 0.80 | KEAP1 (0.46) | KEAP1NFE2L2HCRTR2OXTRGAA | |
| SCHEMBL22234387 | 0.80 | KEAP1 (0.69) | KEAP1NFE2L2OXTRNR1D1 | |
| SCHEMBL6574348 | 0.80 | MMP1 (0.52) | KEAP1NFE2L2HCRTR2OXTRMAPK1 | |
| SCHEMBL6570643 | 0.78 | F2 (0.45) | — | |
| SCHEMBL6574331 | 0.73 | F2 (0.42) | KEAP1NFE2L2HCRTR2OXTR | |
| SCHEMBL6571764 | 0.71 | HCRTR2 (0.43) | KEAP1NFE2L2HCRTR2OXTR | |
| SCHEMBL7423210 | 0.69 | ALDH1A1 (0.55) | KEAP1NFE2L2HCRTR2USP2MAPK1 | |
| SCHEMBL5479473 | 0.68 | HCRTR2 (0.52) | KEAP1NFE2L2HCRTR2USP2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040248897-A1 | Substituted N-acylaniline derivatives, the preparation thereof, and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-12-09 | — | — | US | disclosed |
| EP-1414790-A1 | SUBSTITUTED N-ACYL ANILINE DERIVATIVES, PRODUCTION AND USE THEREOF AS MEDICAMENTS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2004-05-06 | — | — | EP | disclosed |
| WO-2003000653-A1 | SUBSTITUTED N-ACYL ANILINE DERIVATIVES, PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG (DE) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248897-A1 | Substituted N-acylaniline derivatives, the preparation thereof, and their use as pharmaceutical compositions | NAT1, CYP3A5, CYP3A7 | KEAP1 3010/4885NFE2L2 3634/4885HCRTR2 3807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.